重新思考关于肌缩侧面硬化症的第二阶段试验
Michael Benatar1,2, Christopher McDermott3, Martin R Turner4
1Department of Neurology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Brain : a journal of neurology
|December 10, 2024
概括
肌缩侧面硬化症 (ALS) 临床试验经常由于短暂的第二阶段研究和数据解释有缺陷而失败. 改进的第二阶段试验设计对于准确的药物开发和患者希望至关重要.
科学领域:
- 神经学 神经学
- 临床试验设计 临床试验设计
- 药物开发 药物开发
背景情况:
- 肌缩侧面硬化症 (ALS) 研究有治疗方法在有希望的第二阶段结果后在第三阶段试验中失败的历史.
- 目前的第二阶段试验持续时间 (例如6个月) 和结局措施可能不足以治疗ALS,一种进展性神经退行性疾病.
研究的目的:
- 突出二期临床试验设计中的关键问题,用于肌缩性侧面硬化症.
- 倡导改进方法,以确保可靠的数据,以优先考虑第三阶段试验,并防止虚假希望.
主要方法:
- 对ALS临床试验阶段的历史趋势进行批判性审查.
- 分析当前第二阶段研究设计的局限性,包括持续时间,结果指标和数据归算策略.
- 探索用于早期疗效评估的替代代体标记物.
主要成果:
- 在ALS的第二阶段研究往往太短,并依赖于结果测量,这些结果的敏感性不足以检测出有意义的变化.
- 统计方面的挑战,如多重性和不适当的缺失数据归算,可能会损害数据完整性.
- 神经纤维光链减少显示了作为第二阶段去/不去决策的替代标记物的潜力.
结论:
- 在ALS试验中,必须避免对第二阶段数据的过度解释和对探索性分析的乐观报告.
- 改进的第二阶段试验设计,包括适当的统计方法和验证的代用标记,对于高效的药物开发至关重要.
- 优先考虑强大的第二阶段设计,将优化第三阶段试验的资源配置,并最大限度地减少ALS患者的伤害.
相关概念视频
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...